ABOS
Acumen Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Acumen Pharmaceuticals, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
No other changes.
No other changes.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Acumen Pharmaceuticals, Inc..
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Acumen Pharmaceuticals, Inc..
Acumen Pharmaceuticals, Inc.
0.24
0.00 · −1.84%
post 0.22 −4.46%
Tall tick = annual report · Source: EDGAR
Linked news
News
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $56.1M | 43.81% | 0.00% |
| Sands Capital Ventures | $9.9M | 7.76% | 0.00% |
| BlackRockindex-like | $6.6M | 5.20% | +1296.38% |
| Alyeska Investment | $6.6M | 5.12% | 0.00% |
| Franklin Resources | $6.2M | 4.81% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| RA Capital Management | $56.1M | 43.81% | 0.00% |
| Sands Capital Ventures | $9.9M | 7.76% | 0.00% |
| BlackRockindex-like | $6.6M | 5.20% | +1296.38% |
| Alyeska Investment | $6.6M | 5.12% | 0.00% |
| Franklin Resources | $6.2M | 4.81% | 0.00% |
Bull3
Bear1
—